利美索龙(Rimexolone) - 药物靶点：GR_在研适应症：葡萄膜炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Rimexel、Rimexolon、Rimexolone (USP/INN)

+ [8]

靶点

GR

作用机制

GR激动剂(糖皮质激素受体激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构-

非在研机构

Alcon Research Ltd.

Harrow, Inc.

最高研发阶段批准上市

首次获批日期

美国 (1994-12-30),

术后炎症前葡萄膜炎

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C24H34O3

InChIKeyQTTRZHGPGKRAFB-OOKHYKNYSA-N

CAS号49697-38-3

关联

2

项与利美索龙相关的临床试验

NCT02816905 / Completed临床4期IIT

Ocular-hypertensive Response to Topical Steroids in Children After Bilateral Strabismus Surgery (Topical Rimexolone Versus Topical Dexamethasone and Topical Fluorometholone)

This study aims to compare the effects of topical (Rimexolone versus Dexamethasone) on the IOP in children under 13 years of age who underwent bilateral strabismus surgery, and to compare the effects of topical (Rimexolone versus Fluorometholone) on the IOP in the children under 13 years of age who underwent bilateral strabismus surgery.

开始日期2015-10-01

申办/合作机构

Cairo University

NCT00471419 / Completed临床3期

Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye

The purpose of this study is to see if Rimexolone (FID 109980) is a safe and effective treatment of dry eye.

开始日期2006-07-01

申办/合作机构

Alcon Research Ltd.

100 项与利美索龙相关的临床结果

登录后查看更多信息

100 项与利美索龙相关的转化医学

登录后查看更多信息

100 项与利美索龙相关的专利（医药）

登录后查看更多信息

45

项与利美索龙相关的文献（医药）

2021-01-01·Bioengineered4区 · 生物学

Comprehensive analysis of lncRNA-miRNA-mRNA regulatory networks for microbiota-mediated colorectal cancer associated with immune cell infiltration

4区 · 生物学

ArticleOA

作者: Yang, Weimin ; Mao, Linfeng ; Chen, Zhikang ; Chen, Zihua ; Tan, Xiangzhou ; Huang, Changhao ; Guo, Jianping

Recent findings have identified microbiota as crucial participants in many disease conditions, including cancers. Competing endogenous RNA (ceRNA) is regarded as a candidate mechanism involving relevant biological processes. We therefore constructed a ceRNA network using the TCGA and GEO database, to determine the potential mechanisms of microbiota-mediated colorectal carcinogenesis and progression. We found a total of 75 lncRNAs, 8 miRNAs, and 9 mRNAs in the probiotics-mediated ceRNA network and a total of 49 lncRNAs, 4 miRNAs, and 3 mRNA in the pathobiont-mediated ceRNA network, which could induce the microbiota-mediated carcinogenesis and progression. The GO and KEGG analysis indicated that the ceRNA network is mainly enriched in the metabolic process, and two unique pathways (the p53 signaling pathway and microRNA in cancer), respectively. A four-gene signature (FRMD6-AS2, DIRC3, LIFR-AS1, and MRPL23-AS1) was suggested as an independent prognostic factor. Four lncRNAs (LINC00355, KCNQ1OT1, LINC00491, and HOTAIR) were associated with poor survival. Three small molecule candidate anticancer drugs (Pentoxyverine, Rimexolone, and Doxylamine) were identified. A four-gene signature (FAM129A, BCL2, PMAIP1, and RPS6) is significantly correlated with immune infiltration level. This study provides a promising biomarker reservoir to explore the mechanism by which microbiota regulate the ceRNA network involving the immune response, and further participate in colorectal carcinogenesis and progression.

2020-05-01·International ophthalmology4区 · 医学

Outcome and risk of ocular complications of managing children with chronic anterior uveitis with topical rimexolone 1%

4区 · 医学

Article

作者: Zhang, Xiaozhe ; Gepstein, Raz ; Sharief, Lazha ; Wei, Ruoxin ; Tomkins-Netzer, Oren ; Lightman, Sue ; Chen, Yi-Hsing ; Tseng, Hsiao-Jung

PURPOSE:

To investigate the efficacy and safety of 1% rimexolone ophthalmic suspension in children with chronic anterior uveitis under real-life conditions in a tertiary center.

METHODS:

This is a retrospective longitudinal study. Medical records were analyzed at baseline, 1, 3, 6 and 12 months before and after switching to rimexolone for best-corrected visual acuity (BCVA), oral steroid use, number of flares, IOP and anti-glaucoma management.

RESULTS:

Twenty-four patients (41 eyes) diagnosed with either anterior uveitis (n = 25, 60.0%) or panuveitis (n = 16, 40%) were enrolled. The mean age was 10.5 years (4-16 years). The number of patients requiring oral prednisolone reduced from 8 patients (32.0%) at baseline to 3 patients (20.0%) at 12 months (P < 0.001). Following baseline, the median number of uveitis flares reduced from 2.0 (inter-quartile range (IQR) 1.0-2.75) to 1.0 (IQR 0.0-1.0) compared to the 12 months before baseline (P < 0.001). The mean IOP reduced from baseline (22.0 ± 7.3 mmHg) to 1 month (18.8 ± 8.7 mmHg, P = 0.01) and remained stable up to 12 months (15.9 ± 5.0 mmHg, P < 0.001). Average BCVA, dose of oral prednisolone and anti-glaucoma treatments did not change compared to the baseline. The development for IOP ≥ 30 mmHg was associated with a known corticosteroid response [odds ratio (OR) 6.8, P = 0.003] and a dose > 7.5 mg/day oral prednisolone (OR 4.4, P = 0.033).

CONCLUSIONS:

Rimexolone 1% ophthalmic suspension is an effective and safe topical steroid for pediatric anterior uveitis.

2020-01-01·Cornea3区 · 医学

Long-term Outcomes on de novo Ocular Hypertensive Response to Topical Corticosteroids After Corneal Transplantation

3区 · 医学

Article

作者: Salvador-Culla, Borja ; Figueiredo, Francisco Carlos ; Raj, Akash ; Anwar, Hamed ; Sykakis, Evripidis ; Figueiredo, María Socorro

Purpose::

To determine incidence, demographics, management, and outcomes of topical steroid-induced ocular hypertension after penetrating keratoplasty (PKP) and to establish effects on intraocular pressure (IOP) and graft rejection when alternate corticosteroids are used.

Methods::

A single-center, retrospective review of 568 consecutive PKPs performed between 1997 and 2010 was conducted. Data were collected on demographics, best-corrected visual acuity, surgical indications, lens status, IOP, postoperative management, and incidence of rejection.

Results::

Eighty eyes (14.1%) of 74 patients were included. The most common indication was keratoconus (28.8%). Twenty-seven eyes (33.8%) were phakic, 46 (57.4%) had a posterior chamber intraocular lens, and 7 (8.8%) had an anterior chamber intraocular lens. Mean postoperative IOP increase was only significant in the anterior chamber intraocular lens group (18.7 mm Hg, SD 10.4; P = 0.02). The average time for developing hypertension was 9.8 months (SD 14.8) postoperatively, with an average IOP increase of 13.3 mm Hg (SD 5.9). Prednisolone acetate 1% was switched to rimexolone 1% in 64 eyes (80%) and to fluorometholone 0.1% in 16 eyes (20%), which alone achieved IOP normalization in 26 eyes (32.5%) (P < 0.01). Fifty-four eyes (67.5%) required additional antiglaucoma medication. An average IOP reduction of 12.3 mm Hg (SD 6.9) was achieved at an average of 2.3 months (SD 5.2) after the switch. Seventeen eyes (21%) developed glaucoma and 13 eyes (16.3%) developed graft rejection after switching formulations, with no statistically significant differences between rimexolone and fluorometholone (P > 0.05).

Conclusions::

The use of alternate topical corticosteroids may be considered in cases of steroid-induced ocular hypertension after PKP because they offer good antiinflammatory prophylaxis with reduced hypertensive response.

100 项与利美索龙相关的药物交易

登录后查看更多信息